AbbVie Cash on Hand 2010-2019 | ABBV

AbbVie cash on hand from 2010 to 2019. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • AbbVie cash on hand for the quarter ending September 30, 2019 was $10.648B, a 21.21% increase year-over-year.
  • AbbVie cash on hand for 2018 was $8.061B, a 17.65% decline from 2017.
  • AbbVie cash on hand for 2017 was $9.789B, a 52.41% increase from 2016.
  • AbbVie cash on hand for 2016 was $6.423B, a 23.6% decline from 2015.
AbbVie Annual Cash on Hand
(Millions of US $)
2018 $8,061
2017 $9,789
2016 $6,423
2015 $8,407
2014 $8,374
2013 $9,895
2012 $7,976
2011 $653
2010 $11
2009 $
AbbVie Quarterly Cash on Hand
(Millions of US $)
Q3 2019 $10,648
Q2 2019 $5,416
Q1 2019 $5,228
Q4 2018 $8,061
Q3 2018 $8,785
Q2 2018 $3,743
Q1 2018 $9,474
Q4 2017 $9,789
Q3 2017 $9,554
Q2 2017 $7,205
Q1 2017 $6,248
Q4 2016 $6,423
Q3 2016 $7,950
Q2 2016 $8,002
Q1 2016 $8,600
Q4 2015 $8,407
Q3 2015 $9,249
Q2 2015 $8,279
Q1 2015 $7,924
Q4 2014 $8,374
Q3 2014 $10,323
Q2 2014 $10,246
Q1 2014 $9,100
Q4 2013 $9,895
Q3 2013 $9,596
Q2 2013 $8,754
Q1 2013 $7,479
Q4 2012 $7,976
Q3 2012 $4,586
Q2 2012 $75
Q1 2012 $43
Q4 2011 $653
Q3 2011
Q2 2011
Q1 2011
Q4 2010 $11
Q4 2009
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $131.068B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $355.145B 15.39
Roche Holding AG (RHHBY) Switzerland $257.024B 0.00
Merck (MRK) United States $216.154B 16.75
Novartis AG (NVS) Switzerland $206.354B 17.42
Pfizer (PFE) United States $206.312B 12.26
Novo Nordisk (NVO) Denmark $135.639B 23.38
AstraZeneca (AZN) United Kingdom $124.471B 22.48
Sanofi (SNY) France $115.466B 14.19
GlaxoSmithKline (GSK) United Kingdom $109.970B 13.32
Eli Lilly (LLY) United States $108.677B 20.07
Bristol-Myers Squibb (BMY) United States $95.460B 13.35
Bayer (BAYRY) Germany $72.291B 10.71
H Lundbeck (HLUYY) Denmark $6.942B 10.02